Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Phebe J. Wilson"'
Autor:
George Bakris, Albert T. Profy, Jennifer G. Chickering, Jelena P. Seferovic, John P. Hanrahan, Ian H. de Boer, Michael D. Cressman, Mark G. Currie, James Wakefield, G. Todd Milne, Kenneth E. Carlson, Phebe J. Wilson, Yueh-Tyng Chien
Publikováno v:
Clin J Am Soc Nephrol
Background and objectives Impaired nitric oxide signaling through soluble guanylate cyclase has been implicated in the pathophysiology of diabetic kidney disease. Praliciguat, a soluble guanylate cyclase stimulator that amplifies nitric oxide signali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d5a08796e56d4397df9ed0dd1e1a556
https://doi.org/10.2215/cjn.08410520
https://doi.org/10.2215/cjn.08410520
Autor:
Phebe J. Wilson, Margaret M. Redfield, Michael R. Zile, Albert T. Profy, John C. Burnett, Robert S. Mittleman, Jelena P. Seferovic, Gregory D. Lewis, Marvin A. Konstam, Sanjiv J. Shah, James E. Udelson, John D. Parker
Publikováno v:
JAMA
IMPORTANCE: Heart failure with preserved ejection fraction (HFpEF) is often characterized by nitric oxide deficiency. OBJECTIVE: To evaluate the efficacy and adverse effects of praliciguat, an oral soluble guanylate cyclase stimulator, in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d86a9e297b4b1ec0db22347c157d0cf6
https://pubmed.ncbi.nlm.nih.gov/33079136
https://pubmed.ncbi.nlm.nih.gov/33079136
Autor:
Linda Morrow, Daniel P. Zimmer, Jennifer G. Chickering, Jelena P. Seferovic, Andrew L. Frelinger, Kenneth E. Carlson, Phebe J. Wilson, Mark G. Currie, G. Todd Milne, James Wakefield, Joon Jung, Albert T. Profy, John P. Hanrahan, Michael Hall, Alan D. Michelson
Publikováno v:
Diabetologia
Aims/hypothesis Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, amplifies nitric oxide signalling. This exploratory trial investigated the safety, tolerability, pharmacokinetic profile and pharmacodynamic effects of praliciguat in indi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63b4281f0807fbb3e5d7d441113ef655
https://pubmed.ncbi.nlm.nih.gov/31858186
https://pubmed.ncbi.nlm.nih.gov/31858186
Autor:
Jelena P. Seferovic, Marvin A. Konstam, Margaret M. Redfield, Michael R. Zile, James E. Udelson, Robert S. Mittleman, John C. Burnett, Gregory D. Lewis, Sanjiv J. Shah, Albert T. Profy, Phebe J. Wilson, John D. Parker
Publikováno v:
Journal of Cardiac Failure. 26:S8
Introduction Heart failure with preserved ejection fraction (HFpEF) is associated with poor quality of life and increased mortality with exercise intolerance being the main symptom. Hypothesis The soluble guanylate cyclase (sGC) stimulator pralicigua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f64264ae45cca673328eddad32ea37b
https://doi.org/10.1016/j.cardfail.2020.09.030
https://doi.org/10.1016/j.cardfail.2020.09.030
Autor:
Michael Hall, Albert T. Profy, Jennifer G. Chickering, Marina Mihova, James Wakefield, G. Todd Milne, Mark G. Currie, John P. Hanrahan, Dennis Ruff, Phebe J. Wilson, Daniel P. Zimmer
Publikováno v:
Diabetes. 67
Background: Impaired nitric oxide (NO) signaling through soluble guanylate cyclase (sGC) has been associated with microvascular complications of diabetes. Praliciguat (IW-1973), an sGC stimulator that enhances NO signaling, reduced fasting plasma glu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b06acf37ca739e05831e2ed43a90bed
https://doi.org/10.2337/db18-1207-p
https://doi.org/10.2337/db18-1207-p
Autor:
Albert T. Profy, John P. Hanrahan, Michael Hall, Linda Morrow, Jennifer Chickering, G. Todd Milne, Mark Currie, Paul Miller, James D. Wakefield, Phebe J. Wilson
Publikováno v:
Diabetes. 67
Background: Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, has been shown to augment nitric oxide (NO) signaling and reduce fasting plasma glucose and proteinuria in an animal model of diabetic nephropathy. In healthy adults, repeated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4277c36ca5d30aba676de72973390b0f
https://doi.org/10.2337/db18-74-or
https://doi.org/10.2337/db18-74-or
Autor:
Albert T. Profy, G. Todd Milne, Marina Mihova, Michael Hall, Dennis Ruff, James Wakefield, Phebe J. Wilson, Mark G. Currie, Jennifer G. Chickering, John P. Hanrahan
Publikováno v:
Clinical pharmacology in drug development. 8(5)
Nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling is central to the regulation of several physiological processes, including blood flow and inflammation. Deficient NO signaling is implicated in multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::250b35c417ffa1a1a47e3581662896d2
https://pubmed.ncbi.nlm.nih.gov/30422390
https://pubmed.ncbi.nlm.nih.gov/30422390
Autor:
Mark G. Currie, Michael Hall, John P. Hanrahan, Dennis Ruff, B. Joseph Lavins, James Wakefield, Gabrielle Poirier, Phebe J. Wilson, Albert T. Profy
Publikováno v:
Journal of the American College of Cardiology. 67:1284
IW-1973 is an orally active soluble guanylate cyclase (sGC) stimulator that reduces blood pressure (BP) and exhibits anti-fibrotic, anti-inflammatory and organ-protective effects in animal models of systemic hypertension, pulmonary hypertension and h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf7da59ae876929f1eb08504992e04a0
https://doi.org/10.1016/s0735-1097(16)31285-2
https://doi.org/10.1016/s0735-1097(16)31285-2